EFFICACY AND SAFETY OF CEFDINIR IN THE TREATMENT OF PATIENTS WITH ACUTE BRONCHITIS

In this randomized, open-label, dose-comparative study, 18 investigato rs enrolled 466 patients with acute bronchitis. Patients were randomly assigned to receive either 600 mg of cefdinir once daily (QD) or 300 mg of cefdinir twice daily (BID) for 10 days. Both microbiologic and c linical efficacy were assessed at the test-of-cure visit, 7 to 14 days after therapy stopped. A total of 296 patients were classified as ass essable at the test-of-cure visit (n = 150 QD, n = 146 BID). Eradicati on rates of baseline pathogens in these assessable patients were simil ar in both groups; the baseline pathogen eradication rate for assessab le patients in the QD arm was 92%, and that in the BID arm was 93%. Cl inical success (cure or improvement) in assessable patients was 91% an d 93%, respectively. No difference was seen in the incidence of advers e events, in the incidence of diarrhea, or in the incidence of treatme nt withdrawals between the two groups. We conclude that cefdinir is ef fective and safe for the treatment of patients with acute bronchitis.